CD19-targeting CAR T cells have already proved to be powerful immunotherapy agents for B-ALL patients [2, 7] despite differences in each trial in CAR design, conditioning regimens, leukaemia load, patient age, T-cell manufacturing and T-cell dosages [3, 7, 9, 13]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.